SCHEMBL22930637

SCHEMBL22930637

C[C@@H]1[C@H](O)C(COP(=O)(S)O[C@H]2[C@@H](F)[C@H](n3cnc4c(N)ncnc43)O[C@@H]2CO[P@](=O)(O)S)O[C@H]1n1cnc2c(N)ncnc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NT5E P21589 2/20 0.61
▸ P2RY1 P47900 4/20 0.58
▸ P2RY2 P41231 3/20 0.58
▸ SRC P12931 2/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ DNPH1 O43598 1/20 0.58
▸ PRKAB2 O43741 1/20 0.58
▸ TRPM2 O94759 1/20 0.58
▸ LDHA P00338 1/20 0.58
▸ ADRB2 P07550 1/20 0.58
▸ FBP1 P09467 1/20 0.58
▸ ADORA1 P30542 1/20 0.58
▸ PRKAG1 P54619 1/20 0.58
▸ PRKAA2 P54646 1/20 0.58
▸ PDE4D Q08499 1/20 0.58
▸ KCNH2 Q12809 1/20 0.58
▸ PRKAA1 Q13131 1/20 0.58
▸ PDE3A Q14432 1/20 0.58
▸ TAS1R3 Q7RTX0 1/20 0.58
▸ TAS1R1 Q7RTX1 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22930761 0.92 NT5E (0.52) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22930754 0.92 P2RY1 (0.59) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22930773 0.90 NT5E (0.55) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL24538537 0.89 P2RY1 (0.71) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22340335 0.88 NT5E (0.48) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22930788 0.87 RNASEL (0.60) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL23476718 0.86 NT5E (0.55) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22381966 0.86 NT5E (0.80) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22930743 0.86 NT5E (0.48) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22434529 0.86 NT5E (0.56) NT5EP2RY1P2RY2SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10906930-B2 Compositions and methods for activating “stimulator of interferon gene”-dependent signalling CHINOOK THERAPEUTICS, INC. (US) 2021-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906930-B2 Compositions and methods for activating “stimulator of interferon gene”-dependent signalling STING1, IRF3, CGAS NT5E 83/4885P2RY1 38/4885P2RY2 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback